Rep. Gilbert Cisneros Buys Boston Scientific (BSX) Stock
Gilbert Cisneros purchased Boston Scientific shares valued between $1,001 and $15,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Gilbert Cisneros bought between $1,001 and $15,000 of Boston Scientific Corporation ($BSX) stock on May 11, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed June 9, 2026.
Since the trade, $BSX is up 4.8% after 1 week, down 9.4% after 1 month and down 16.8% to date (from the $53.37 close on May 11, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Cisneros (D-CA)
- Status:
- Member — House
- State/District:
- CA-31
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 9, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Boston Scientific Corporation ($BSX) | Buy | May 11, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
BSX
Boston Scientific Corporation
Key Points
- Gilbert Cisneros, a member of the U.S. House, bought Boston Scientific shares valued between $1,001 and $15,000 on May 11, 2026.
- Boston Scientific, trading on the NYSE under BSX, has a market cap of $69.7 billion and a P/E ratio of 19.63.
- Analysts recently maintained positive ratings on Boston Scientific, with price targets ranging from $55 to $89.
Get $BSX trade alerts by text
We text you when insiders, Congress or big funds trade $BSX. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Boston Scientific Corporation alert may contain errors. Disclosures
On May 11, 2026, Gilbert Cisneros, a member of the U.S. House, bought shares of Boston Scientific Corporation, trading under the ticker BSX on the NYSE. The transaction was valued between $1,001 and $15,000, according to the STOCK Act disclosure filed on June 9, 2026.
Gilbert Cisneros vs. the S&P 500
Hypothetical returns from Gilbert Cisneros's disclosed trades, not real profit or advice. How we model this.
Boston Scientific Corporation Stock Up 8.6%
Shares of NYSE:BSX traded near $46.99 at the time of the report. Boston Scientific has a market cap of about $69.7 billion. The company maintains a P/E ratio of 19.63 and a forward P/E of 12.59, indicating investor expectations for future earnings. Its beta is 0.559, suggesting lower volatility compared to the market. The stock has ranged from a 52-week low of $45.99 to a high of $109.50, with a 50-day moving average of $56.54 and a 200-day moving average of $82.70.
Recent Earnings
Boston Scientific reported revenue of $20.61 billion, with a growth rate of 11.6%. The company achieved a net margin of 17.29% and a return on equity of 14.66%. Investors can expect the next earnings report on July 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
12 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 0.7%. Revenue met estimates.
-
Profit surprise
EBITDA met by 0 percent. Operating income missed by 13 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 12 target cuts.
-
Earnings quality
Gross margin up 6.2 points. Operating margin up 1.4 points. Positive free cash flow.
Earnings Call Summary
Boston Scientific reported first quarter sales of $5.2 billion, up 9.4 percent, and beat on earnings at $0.80 per share. However, management revealed major headwinds in three key franchises. The EP cardiology ablation business, which grew 22 percent this quarter, is now expected to slow to 10 percent full year as competition from Medtronic, J and J, and Abbott pressures U.S. share. WATCHMAN, which grew 19 percent, slowed sharply in February as stand-alone procedures fell even as concomitant adoption grew. Urology nearly flatlined at 1 percent growth due to problems in stone management and sacral neuromodulation. Management said the company lost more market share than expected and hospital capacity constraints are limiting WATCHMAN procedure volume.
Guidance The company cut its full year sales growth guidance from an expected 8 to 10 percent range down to 6.5 to 8 percent. They expect second quarter sales to grow only 5 to 7 percent year over year. The company now guides full year earnings per share to $3.34 to $3.41, still up 9 to 11 percent but well below prior expectations.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Analysts Set New Price Targets
Several analysts have maintained their positive outlook on Boston Scientific. On June 4, 2026, Truist Securities maintained a 'buy' rating with a price target of $64. BTIG also kept a 'buy' rating, targeting $65, while Canaccord Genuity set a target of $70 on June 1, 2026. The consensus among 30 analysts is a 'strong buy' with a mean target price of $78.17.
About Boston Scientific
Boston Scientific Corporation, headquartered in Marlborough, Massachusetts, is a major player in the healthcare sector, specifically in medical devices. Under the leadership of CEO Michael F. Mahoney, the company develops and markets a wide range of products for medical specialties worldwide. With approximately 59,000 employees, Boston Scientific operates in MedSurg and Cardiovascular segments, providing devices for gastrointestinal, urological, cardiovascular, and neurological treatment.
Bottom Line
Investors often monitor stock trades by politicians like Gilbert Cisneros to gauge potential interest or insights. His recent purchase of Boston Scientific shares reflects a personal financial decision. It's important to note that these disclosures are made after the fact and don't necessarily reflect current holdings.
Related Filing Alerts
Source: Gilbert Cisneros's STOCK Act disclosure on $BSX (May 11, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts